Thus, MD achieves a long-term anti-inflammatory effect through the diminution of plasma TNF-α, IFN-γ, and IL-1β, which are molecules involved in the response of NF-κβ, and also reduces inflammation via IL-1β, rather than IL-18. The gene discussed is TNF; the disease is Menkes disease.